Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGGT006 in Refractory Hypercholesterolemia
NCT06293729Phase 1Not yet recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
01
Overview
Phase 1, open-label trial of NGGT006 in familial hypercholesterolemia (FH) (3 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoints: Adverse Events and Serious Adverse Events at 52 weeks and Low-Density Lipoprotein Cholesterol at 52 weeks. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
NGGT006
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT06293729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293729.